vorinostat has been researched along with Dyspnea in 1 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
Dyspnea: Difficult or labored breathing.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Vorinostat dose levels were 200, 300, and 400 mg orally once daily for 14 days." | 2.84 | Vorinostat and Concurrent Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Brain Metastases: A Phase 1 Dose Escalation Trial. ( Adler, JR; Chang, SD; Choi, CYH; Harsh, GR; Modlin, LA; Neal, JW; Pinder-Schenck, MC; Soltys, SG; Wakelee, HA; Yu, HM, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, CYH | 1 |
| Wakelee, HA | 1 |
| Neal, JW | 1 |
| Pinder-Schenck, MC | 1 |
| Yu, HM | 1 |
| Chang, SD | 1 |
| Adler, JR | 1 |
| Modlin, LA | 1 |
| Harsh, GR | 1 |
| Soltys, SG | 1 |
1 trial available for vorinostat and Dyspnea
| Article | Year |
|---|---|
Vorinostat and Concurrent Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Brain Metastases: A Phase 1 Dose Escalation Trial.
Topics: Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Administratio | 2017 |